These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
357 related articles for article (PubMed ID: 34423856)
1. Structural Biology of LRRK2 and its Interaction with Microtubules. Leschziner AE; Reck-Peterson SL Mov Disord; 2021 Nov; 36(11):2494-2504. PubMed ID: 34423856 [TBL] [Abstract][Full Text] [Related]
2. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules. Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024 [TBL] [Abstract][Full Text] [Related]
3. The Cell Biology of LRRK2 in Parkinson's Disease. Usmani A; Shavarebi F; Hiniker A Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455 [TBL] [Abstract][Full Text] [Related]
4. Structure of LRRK2 in Parkinson's disease and model for microtubule interaction. Deniston CK; Salogiannis J; Mathea S; Snead DM; Lahiri I; Matyszewski M; Donosa O; Watanabe R; Böhning J; Shiau AK; Knapp S; Villa E; Reck-Peterson SL; Leschziner AE Nature; 2020 Dec; 588(7837):344-349. PubMed ID: 32814344 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of Parkinson's disease-related LRRK2 by type I and type II kinase inhibitors: Activity and structures. Sanz Murillo M; Villagran Suarez A; Dederer V; Chatterjee D; Alegrio Louro J; Knapp S; Mathea S; Leschziner AE Sci Adv; 2023 Dec; 9(48):eadk6191. PubMed ID: 38039358 [TBL] [Abstract][Full Text] [Related]
6. The In Situ Structure of Parkinson's Disease-Linked LRRK2. Watanabe R; Buschauer R; Böhning J; Audagnotto M; Lasker K; Lu TW; Boassa D; Taylor S; Villa E Cell; 2020 Sep; 182(6):1508-1518.e16. PubMed ID: 32783917 [TBL] [Abstract][Full Text] [Related]
8. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease. Xiong Y; Dawson VL; Dawson TM Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868 [TBL] [Abstract][Full Text] [Related]
9. Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2. Chen S; Basiashvili T; Hutchings J; Murillo MS; Suarez AV; Louro JA; Leschziner AE; Villa E bioRxiv; 2024 Jun; ():. PubMed ID: 38948781 [TBL] [Abstract][Full Text] [Related]
10. A designed ankyrin-repeat protein that targets Parkinson's disease-associated LRRK2. Dederer V; Sanz Murillo M; Karasmanis EP; Hatch KS; Chatterjee D; Preuss F; Abdul Azeez KR; Nguyen LV; Galicia C; Dreier B; Plückthun A; Versees W; Mathea S; Leschziner AE; Reck-Peterson SL; Knapp S J Biol Chem; 2024 Jul; 300(7):107469. PubMed ID: 38876305 [TBL] [Abstract][Full Text] [Related]
11. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease. Seol W BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607 [TBL] [Abstract][Full Text] [Related]
12. Roc, the G-domain of the Parkinson's disease-associated protein LRRK2. Park Y; Liao J; Hoang QQ Trends Biochem Sci; 2022 Dec; 47(12):1038-1047. PubMed ID: 35840518 [TBL] [Abstract][Full Text] [Related]
13. From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease. Herbst S; Lewis PA Biochem J; 2021 Jul; 478(14):2945-2951. PubMed ID: 34328508 [TBL] [Abstract][Full Text] [Related]
14. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease. Monfrini E; Di Fonzo A Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276 [TBL] [Abstract][Full Text] [Related]
15. Pathological Functions of LRRK2 in Parkinson's Disease. Jeong GR; Lee BD Cells; 2020 Nov; 9(12):. PubMed ID: 33266247 [TBL] [Abstract][Full Text] [Related]